Safety, efficacy and pharmacokinetics of low-dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus

Article Rheumatology

Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: A self-controlled before-after trial

Li Sun et al.

Summary: Telitacicept combined with standard treatment significantly improves the efficacy and reduces the glucocorticoid dosage in refractory childhood-onset systemic lupus erythematosus (cSLE), and also shows efficacy on lupus nephritis. The related adverse drug events are controllable.

LUPUS (2022)

Add to Collection

Article Pharmacology & Pharmacy

Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein for the treatment of systemic lupus erythematosus

Yong Fan et al.

Summary: This review provides a comprehensive overview of the preclinical and clinical activity of telitacicept in systemic lupus erythematosus (SLE), showing that telitacicept in combination with standard therapy can provide clinical benefit and is well tolerated in Chinese patients.

DRUGS OF TODAY (2022)

Add to Collection

Article Rheumatology

Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity

Diogo Jesus et al.

Summary: The SLE-DAS is an accurate and user-friendly tool for defining SLE clinical remission state and disease activity categories, validated against expert assessment and BILAG index.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Pharmacology & Pharmacy